Table 3.
Base-case cost-effectiveness results from the Chinese private payers perspective
| Cost, CNY | QALY | ICER, CNY | |||
|---|---|---|---|---|---|
| Total | Incremental | Total | Incremental | ||
| PEACE | |||||
| Statins | 324863.85 | NA | 8.19 | NA | NA |
| Statins + Evo 140mgQ2W | 368018.46 | 43154.61 | 8.54 | 0.35 | 121986.67 |
| Statins + Evo 420mgQM | 395266.35 | 70402.50 | 8.54 | 0.35 | 199009.25 |
| BERSONa | |||||
| Statins | 306842.49 | NA | 9.64 | NA | NA |
| Statins + Evo 140mgQ2W | 351529.31 | 44686.82 | 10.18 | 0.54 | 83078.56 |
| Statins + Evo 420mgQM | 387231.89 | 80389.40 | 10.13 | 0.49 | 165565.29 |
| SuValue®, LDL-C ≥ 100 mg/dl | |||||
| Statins | 330228.73 | NA | 8.33 | NA | NA |
| Statins + Evo 140mgQ2W | 346469.52 | 16240.78 | 8.92 | 0.59 | 27423.06 |
| Statins + Evo 420mgQM | 375671.63 | 45442.90 | 8.92 | 0.59 | 76731.73 |
| SuValue®, LDL-C ≥ 70 mg/dl | |||||
| Statins | 312147.77 | NA | 8.39 | NA | NA |
| Statins + Evo 140mgQ2W | 340101.64 | 27953.87 | 8.86 | 0.48 | 58806.29 |
| Statins + Evo 420mgQM | 369069.97 | 56922.20 | 8.86 | 0.48 | 119746.70 |
CNY, Chinese Yuan; Evo 140mgQ2W, evolocumab 140 mg every 2 weeks; Evo 420mgQM, evolocumab 420 mg monthly; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable
a: The background statin in the BERSON study was atorvastatin 20 mg/d